Semi-synthetic deriv of abamectin, q.v., consists of a mixture of not less than 80% component B1a and not more than 20% component B1b. Prepn: JP Kokai 79 61198; J. C. Chabala, M. H. Fisher, US 4199569 (1979, 1980 both to Merck & Co.); J. C. Chabala et al., J. Med. Chem. 23, 1134 (1980). Irreversible effects on adult parasites in onchocerciasis: A. P. Plaisier et al., J. Infect. Dis. 172, 204 (1995). Metabolism in animals: S.-H. L. Chiu et al., Drug Metab. Dispos. 14, 590 (1986). Pharmacokinetics in horses and sheep: S. E. Marriner et al., J. Vet. Pharmacol. Ther. 10, 175 (1987). HPLC determn in cattle and sheep tissues: P. C. Tway et al., J. Agric. Food Chem. 29, 1059 (1981); in human plasma and milk: R. Chiou et al., J. Chromatogr. 416, 196 (1987). Review of early chemistry and biology: W. C. Campbell et al., Science 221, 823-828 (1983). Review of clinical use and pharmacology: W. C. Campbell, G. W. Benz, J. Vet. Pharmacol. Ther. 7, 1-16 (1984); T. B. Barragry, Can. Vet. J. 28, 512-517 (1987); of pharmacology: J. L. Bennett et al., Parasitol. Today 4, 226-228 (1988). Book: Ivermectin and Abamectin, W. C. Campbell, Ed. (Springer-Verlag, New York, 1989) 363 pp. Review in filariasis: D. Richard-Lenoble et al., Fundam. Clin. Pharmacol. 17, 199-203 (2003); in dermatologic applications: A. L. Dourmishev et al., Int. J. Dermatol. 44, 981-988 (2005). See also: Avermectins.
Anthelmintic (Onchocerca).
Anthelmintic (Nematodes)